Foundayo FAQ: 15 real questions about the weight-loss pill, answered

Foundayo is the brand name for orforglipron, a once-daily weight-loss tablet developed by Eli Lilly. The US FDA approved it on 1 April 2026 for adults with obesity — or some adults with overweight who also have a weight-related medical problem — to reduce excess body weight and keep it off, alongside a reduced-calorie diet and more physical activity.^[1] It is the first GLP-1 weight-loss medicine in tablet form that can be taken at any time of day, without food or water restrictions.^[1] It was licensed in the UK by the MHRA on 10 August 2026.^[6]

Yes. Orforglipron is a GLP-1 receptor agonist — the same drug class as semaglutide (Wegovy, Rybelsus). What sets it apart is chemistry: it is a small molecule rather than a peptide.^[2] Peptide GLP-1s are fragile in the gut, which is why most are injections and why the one existing peptide tablet comes with strict dosing rules. A small molecule survives digestion, so it can be swallowed like an ordinary tablet — and manufactured by chemical synthesis at much larger scale than injectable peptides.^[1]

The pivotal evidence is ATTAIN-1, a 72-week, placebo-controlled phase 3 trial in 3,127 adults with obesity or overweight (without diabetes), published in the New England Journal of Medicine. At the highest research dose, participants lost an average of 12.4% of body weight (about 12.4 kg), versus 0.9% with placebo.^[2] Nearly six in ten top-dose participants (59.6%) lost at least 10% of their body weight, and 39.6% lost 15% or more.^[2] Blood pressure, triglycerides and non-HDL cholesterol also improved.^[2]

Only if a qualified prescriber decides it is suitable for you. Foundayo has been licensed by the MHRA since 10 August 2026, for adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition, and for type 2 diabetes.^[6] In the UK it is available by private prescription only — not on the NHS — and it is a prescription-only medicine, used alongside diet and physical activity.^[9] Suitability is an individual clinical decision: a prescriber must weigh your history, other medicines and the contraindications covered in question 13. Nothing on this page is medical advice.

It already is. The MHRA licensed Foundayo on 10 August 2026 — the first authorisation anywhere in Europe — and Lilly UK announced on 24 August 2026 that it is available in the UK via private prescription.^[6][9] NHS availability is a separate, later step: NICE's appraisal is expected to publish on 18 November 2026 (see question 15).^[10] Our UK availability tracker follows the position as it develops.

Only through the proper route. Foundayo is a prescription-only medicine: lawful UK supply means a consultation and prescription from a qualified prescriber, dispensed by a regulated pharmacy. Any website offering it to UK customers without a prescription is breaking the law, whatever it claims, and anything shipped that way cannot be assumed to be genuine orforglipron, correctly dosed, or made to any safety standard. Unlicensed weight-loss products sold online have a well-documented counterfeiting problem — the MHRA runs a dedicated #FakeMeds campaign warning about exactly this. If you have taken a product sold as Foundayo and feel unwell, speak to your GP or pharmacist and report it via the MHRA Yellow Card scheme.^[7]

Both are GLP-1 receptor agonists used for weight management, but they differ in form and chemistry: Wegovy (semaglutide) is a peptide given by injection, while Foundayo (orforglipron) is a small-molecule once-daily tablet.^[2] On effectiveness, be wary of direct comparisons: Foundayo's phase 3 trials tested it against placebo, not against Wegovy, so there are no published head-to-head numbers in the sources this site uses.^[2] Trial populations and designs differ, which makes cross-trial percentage comparisons unreliable. Both are now licensed in the UK, and choosing between them is a prescriber-led decision.

They are different medicines from the same manufacturer, Eli Lilly. Mounjaro (tirzepatide) is an injection; Foundayo (orforglipron) is a daily tablet.^[1] As with Wegovy, Foundayo's trials were placebo-controlled, so no like-for-like head-to-head trial results have been published — meaning nobody can honestly tell you which "loses more weight" for a given person.^[2] The practical differences a prescriber would weigh are route (tablet versus injection), tolerability, individual response, and UK availability and cost. Lilly reported Foundayo's cardiometabolic improvements as consistent with injectable GLP-1 medicines.^[4]

Rybelsus (oral semaglutide) is another GLP-1 tablet, but it is a peptide, so it comes with absorption rules: it must be taken on an empty stomach with a small amount of plain water, followed by a wait before eating, drinking or taking other medicines. Foundayo is a small molecule, so it needs none of that — Lilly's headline claim is that it is the only GLP-1 weight-loss pill that can be taken at any time of day without food or water restrictions.^[1] Rybelsus is also licensed for type 2 diabetes rather than weight management.^[8]

One tablet, once a day, at any time — with or without food or water.^[5] Treatment starts at the lowest strength, 0.8 mg, and is stepped up gradually, staying at least 30 days on each step before increasing.^[5] That slow escalation is deliberate: it reduces the risk of the gut-related side effects common to all GLP-1 medicines. The maintenance dose — anywhere from 5.5 mg to the 17.2 mg maximum — is chosen by the prescriber based on response and tolerability, not by the patient.^[5] Our dosage guide walks through the full titration schedule.

Six tablet strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, taken once daily.^[1] The usual maintenance range is 5.5 mg to 17.2 mg.^[5] One point of frequent confusion: the trial reports talk about 6 mg, 12 mg and 36 mg doses. Those were research dose labels used in the ATTAIN programme and do not match the marketed tablet strengths — so don't try to map "36 mg" onto a pharmacy product.^[2] The prescribing strengths are the six listed above.

Mostly gut-related, dose-related and typical of the GLP-1 class. In ATTAIN-1, at the highest dose: nausea 33.7% (vs 10.4% placebo), constipation 25.4%, diarrhoea 23.1% and vomiting 24.0%; most cases were mild to moderate.^[2] The label also lists indigestion, abdominal pain, headache, fatigue, belching, heartburn and hair loss among common effects.^[1] 10.3% of top-dose participants stopped treatment because of adverse events, versus 2.7% on placebo.^[2] In the UK, suspected side effects of any medicine should be reported via the MHRA Yellow Card scheme. See our full side-effects guide.

Under the US label, Foundayo is contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and it carries the GLP-1 class warning about thyroid C-cell tumours seen in rodent studies.^[1] Further warnings and precautions cover acute pancreatitis, severe gastrointestinal reactions, gallbladder disease, kidney injury from dehydration caused by vomiting or diarrhoea, hypoglycaemia when combined with insulin or sulfonylureas, and monitoring for diabetic retinopathy and mood changes.^[1] Screening for all of this is exactly why a prescriber, not a website, decides suitability.

Yes, though — as with the whole GLP-1 class — weight loss is somewhat smaller in people with type 2 diabetes. In ATTAIN-2, a 72-week trial in more than 1,600 adults with obesity or overweight plus type 2 diabetes, the highest dose produced 10.5% average weight loss versus 2.2% with placebo.^[4] It also cut HbA1c by up to 1.8 percentage points from a baseline of 8.1%, with 75% of top-dose participants reaching an A1C of 6.5% or below.^[4] About half of top-dose participants lost at least 10% of their body weight.^[4]

Foundayo is available privately in the UK, and private prices vary between regulated providers; it is worth checking what a fee includes. This site does not quote prices or name providers. It is not available on the NHS. NHS access requires a NICE appraisal of clinical and cost effectiveness, which is under way: NICE lists orforglipron for managing overweight and obesity as in development, with publication expected on 18 November 2026.^[10] As with Mounjaro and Wegovy, any recommendation would likely be restricted to defined patient groups rather than open access.